What the FDA labels say about taking them together
Cyclosporine and ranolazine
Ranolazine's FDA label of January 23, 2026 names cyclosporine in its drug interactions section; the cyclosporine labels PlainMeds reads (4) do not name ranolazine. The ranolazine label: “P-gp inhibitors (e.g., cyclosporine): Ranolazine exposure increased.”
Check it at the source: the cyclosporine FDA label on DailyMed (effective August 10, 2026, Novartis Pharmaceuticals Corporation); the ranolazine FDA label on DailyMed (effective January 23, 2026, Glenmark Pharmaceuticals Inc., USA).
What does the cyclosporine label say about ranolazine?
Cyclosporine's label (effective August 10, 2026) and its 3 other brand-application labels do not name ranolazine in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Neoral), Novartis Pharmaceuticals Corporation, effective August 10, 2026 (SPL set 94461af3-11f1-4670-95d4-2965b9538ae3), via openFDA; the full label on DailyMed
What does the ranolazine label say about cyclosporine?
Ranolazine label, drug interactionsP-gp inhibitors (e.g., cyclosporine): Ranolazine exposure increased.
Aspruzyo Sprinkle label (SUN PHARMACEUTICAL INDUSTRIES, INC., January 29, 2025), drug interactionsDRUG INTERACTIONS Moderate CYP3A inhibitors (e.g., diltiazem, verapamil, erythromycin): Limit ASPRUZYO Sprinkle to 500 mg twice daily. (7.1) P-gp inhibitors (e.g., cyclosporine):
Source: FDA drug label (Aspruzyo Sprinkle, NDA216018), SUN PHARMACEUTICAL INDUSTRIES, INC., effective January 29, 2025 (SPL set dd9f81e4-50da-4551-aed5-559d304df42e), via openFDA
Source: FDA drug label (Ranolazine), Glenmark Pharmaceuticals Inc., USA, effective January 23, 2026 (SPL set 0cf58732-c242-49b0-8e3f-248778b4458d), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Cyclosporine | Ranolazine | |
|---|---|---|
| Labeled for | Organ transplant rejection, Rheumatoid arthritis | Angina |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $1.04 per unit 0.05% eye emulsion | $0.165 per tablet 500 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once